Evaluation of a Project Integrating Financial Incentives into a Hepatitis C Testing and Treatment Model of Care at a Sexual Health Service in Cairns, Australia, 2020–2021
Viruses · 2024
DOI: 10.3390/v16050800 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Joshua Dawe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Disease Elimination, Burnet Institute, Melbourne 3004, Australia. Hauptthemen laut MEDLINE: Hepatitis C, Motivation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Paul Ramsay Foudnation, EC Australia, Burnet Institute.
Abstract (Originalsprache)
Background
Understanding the effectiveness of novel models of care in community-based settings is critical to achieving hepatitis C elimination. We conducted an evaluation of a hepatitis C model of care with financial incentives that aimed to improve engagement across the hepatitis C cascade of care at a sexual health service in Cairns, Australia.
Methods
Between March 2020 and May 2021, financial incentives were embedded into an established person-centred hepatitis C model of care at Cairns Sexual Health Service. Clients of the Service who self-reported experiences of injecting drugs were offered an AUD 20 cash incentive for hepatitis C testing, treatment initiation, treatment completion, and test for cure. Descriptive statistics were used to describe retention in hepatitis C care in the incentivised model. They were compared to the standard of care offered in the 11 months prior to intervention.
Results
A total of 121 clients received financial incentives for hepatitis C testing (antibody or RNA). Twenty-eight clients were hepatitis C RNA positive, of whom 92% (24/28) commenced treatment, 75% (21/28) completed treatment, and 68% (19/28) achieved a sustained virological response (SVR). There were improvements in the proportion of clients diagnosed with hepatitis C who commenced treatment (86% vs. 75%), completed treatment (75% vs. 40%), and achieved SVR (68% vs. 17%) compared to the pre-intervention comparison period.
Conclusions
In this study, financial incentives improved engagement and retention in hepatitis C care for people who inject drugs in a model of care that incorporated a person-centred and flexible approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Disease Elimination, Burnet Institute, Melbourne 3004, Australia.
- Cairns Sexual Health Service, Cairns 4870, Australia.
- School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia.
- Melbourne School of Population and Global health, University of Melbourne, Melbourne 3010, Australia.
- Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne 3086, Australia.
- Department of Infectious Diseases, Alfred Health and Monash University, Melbourne 3004, Australia.
Förderung
- Paul Ramsay Foudnation
- EC Australia
- Burnet Institute
Zitieren
APA
Dawe, J., Gorton, C., Lewis, R., Richmond, J. A., Wilkinson, A. L., Pedrana, A., Stoové, M., Doyle, J. S., & Russell, D. (2024). Evaluation of a Project Integrating Financial Incentives into a Hepatitis C Testing and Treatment Model of Care at a Sexual Health Service in Cairns, Australia, 2020–2021. Viruses. https://doi.org/10.3390/v16050800
Vancouver
Dawe J, Gorton C, Lewis R, Richmond JA, Wilkinson AL, Pedrana A, et al. Evaluation of a Project Integrating Financial Incentives into a Hepatitis C Testing and Treatment Model of Care at a Sexual Health Service in Cairns, Australia, 2020–2021. Viruses. 2024. doi:10.3390/v16050800
BibTeX
@article{Dawe2024,
author = {Dawe, Joshua and Gorton, Carla and Lewis, Rhondda and Richmond, Jacqueline A and Wilkinson, Anna L and Pedrana, Alisa and Stoové, Mark and Doyle, Joseph S and Russell, Darren},
title = {Evaluation of a Project Integrating Financial Incentives into a Hepatitis C Testing and Treatment Model of Care at a Sexual Health Service in Cairns, Australia, 2020–2021},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16050800}
}
EUVIMED